Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the rectum.
Biomarker and diagnostic research for rectal neuroendocrine tumor has been reported in the published literature.
3 clinical trials registered. Interventions under study include procedural interventions. Pipeline includes 3 NA. Research is primarily sponsored by academic and government institutions.
201 publications have been identified in PubMed for rectal neuroendocrine tumor. Research spans Review / Meta-Analysis (25%), Clinical Trial Publication (25%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 50 | 25% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 2:59 PM UTC
European rare disease database
Clinical study results |
50 |
25% |
Testing and diagnosis research | 28 | 14% |
Laboratory research | 26 | 13% |
Patient case studies | 25 | 12% |
Disease patterns and progression | 19 | 9% |
New treatment approaches | 2 | 1% |
Other research | 1 | 0% |
Cella L (2026). [PMID: 42041162](https://pubmed.ncbi.nlm.nih.gov/42041162/). *Future Oncol*. [Review / Meta-Analysis]
Khayyat M (2026). [PMID: 41607754](https://pubmed.ncbi.nlm.nih.gov/41607754/). *World journal of gastrointestinal oncology*. [Review / Meta-Analysis]
Kong QL (2026). [PMID: 41846887](https://pubmed.ncbi.nlm.nih.gov/41846887/). *Frontiers in medicine*. [Case Report / Case Series]
Fukui Y (2026). [PMID: 41733126](https://pubmed.ncbi.nlm.nih.gov/41733126/). *Diseases of the colon and rectum*. [Case Report / Case Series]
Su J (2026). [PMID: 41653198](https://pubmed.ncbi.nlm.nih.gov/41653198/). *Cancer Immunol Immunother*. [Review / Meta-Analysis]
Tanguy R (2026). [PMID: 42115465](https://pubmed.ncbi.nlm.nih.gov/42115465/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Chang HY (2026). [PMID: 41863012](https://pubmed.ncbi.nlm.nih.gov/41863012/). *J Pathol*. [Clinical Trial Publication]
Iizuka T (2026). [PMID: 42073592](https://pubmed.ncbi.nlm.nih.gov/42073592/). *Cancers (Basel)*. [Clinical Trial Publication]
Kennecke H (2026). [PMID: 41562331](https://pubmed.ncbi.nlm.nih.gov/41562331/). *Endocr Relat Cancer*. [Review / Meta-Analysis]
Li Y (2026). [PMID: 41862827](https://pubmed.ncbi.nlm.nih.gov/41862827/). *BMC Cancer*. [Epidemiology / Natural History]
AI-curated news mentioning rectal neuroendocrine tumor
Updated Sep 2, 2026
A recent study highlights the significance of late recurrence in patients with rectal neuroendocrine tumors, particularly focusing on delayed hepatic metastasis. This research may influence future monitoring and treatment strategies for affected patients.
A systematic review and meta-analysis compares modified endoscopic mucosal resection and endoscopic submucosal dissection for rectal neuroendocrine tumors measuring 10 mm or less. This study provides insights into treatment efficacy for this specific tumor size.